Overview

A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer

Status:
Active, not recruiting

Trial end date:
2021-11-16

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety and efficacy of nab-paclitaxel and gemcitabine with or without olaratumab in the treatment of first-line metastatic pancreatic cancer.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Albumin-Bound Paclitaxel
Gemcitabine
Olaratumab
Paclitaxel